ClinicalTrials.Veeva

Menu

Influence of Cerebral Oedema in Intracerebral Haemorrhage (COPITCH)

U

University Hospital, Lille

Status

Enrolling

Conditions

Intra Cerebral Hemorrhage
Stroke

Treatments

Radiation: Brain MRI
Biological: Biological biomarkers

Study type

Interventional

Funder types

Other

Identifiers

NCT04621357
2019-A02502-55 (Other Identifier)
2017_70

Details and patient eligibility

About

In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides stroke unit care, no specific treatment has been proven effective yet. Perihaematomal oedema (PHO) could be a promising therapeutic target. However, the mechanisms, the natural history as well as the clinical impact of this PHO remain unclear. The COPITCH study has been designed to answer these questions

Enrollment

500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • With a spontaneous ICH, i.e. non traumatic
  • Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset
  • Patient insured under the French social security
  • Consent form signed

Exclusion criteria

  • Pure intraventricular haemorrhages
  • "secondary" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic transformation within an infarct
  • Pre-admission modified Rankin score of 4 or 5
  • Life expectancy of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)
  • Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done)
  • Adults who are deprived of their liberty by judicial or administrative decision
  • Referral from other hospitals
  • Contra-indication to MRI : claustrophobia, ocular metallic foreign bodies (accidental or other) or in a risk area (nervous or vascular system);irremovable implanted medical device (pacemaker, neurostimulator, cochlear implants and others);metallic heart valve (mainly old heart valves) or vascular clips previously implanted on cranial aneurysms; gadolinium allergy
  • No consent form

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

500 participants in 1 patient group

Patient with intracerebral haemorrhage
Experimental group
Description:
Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.
Treatment:
Biological: Biological biomarkers
Radiation: Brain MRI

Trial contacts and locations

1

Loading...

Central trial contact

Charlotte Cordonnier, MD,PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems